First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapy

Nizar Tannir, Hans Hammers, Asim Amin

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Despite improved outcomes with systemic vascular endothelial growth factor (VEGF)-targeted agents in patients with advanced renal cell carcinoma (RCC), the majority of patients will eventually develop treatment resistance and disease progression. With the emergence of checkpoint inhibitors as potential treatment approaches, studies suggest that ideally combining or sequencing them with VEGF receptor (VEGFR)–tyrosine kinase inhibitors (TKIs) may provide more effective treatments that reduce or delay disease progression. Indeed, preliminary evidence suggests that VEGFR-TKIs can reverse immunosuppressive effects in the tumor microenvironment, potentially enhancing the effects of subsequent immunotherapy with checkpoint inhibitors. However, questions remain regarding the most effective treatment sequences or combinations with VEGFR-TKIs and checkpoint inhibitors. This review discusses the potential role of first-line VEGFR-TKIs in priming the tumor microenvironment for immunotherapy.

Original languageEnglish (US)
Pages (from-to)825-831
Number of pages7
JournalCurrent Medical Research and Opinion
Volume34
Issue number5
DOIs
StatePublished - May 4 2018

Fingerprint

Vascular Endothelial Growth Factor Receptor
Tumor Microenvironment
Renal Cell Carcinoma
Protein-Tyrosine Kinases
Immunotherapy
Vascular Endothelial Growth Factor A
Disease Progression
Proxy
Therapeutics
Immunosuppressive Agents

Keywords

  • Carcinoma
  • immunotherapy
  • pazopanib
  • renal cell
  • renal cell carcinoma
  • tyrosine kinase inhibitor
  • vascular endothelial growth factor

ASJC Scopus subject areas

  • Medicine(all)

Cite this

First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma : priming the tumor microenvironment for immunotherapy. / Tannir, Nizar; Hammers, Hans; Amin, Asim.

In: Current Medical Research and Opinion, Vol. 34, No. 5, 04.05.2018, p. 825-831.

Research output: Contribution to journalReview article

@article{354be6e2657f4bd4a44366218b5d4f12,
title = "First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapy",
abstract = "Despite improved outcomes with systemic vascular endothelial growth factor (VEGF)-targeted agents in patients with advanced renal cell carcinoma (RCC), the majority of patients will eventually develop treatment resistance and disease progression. With the emergence of checkpoint inhibitors as potential treatment approaches, studies suggest that ideally combining or sequencing them with VEGF receptor (VEGFR)–tyrosine kinase inhibitors (TKIs) may provide more effective treatments that reduce or delay disease progression. Indeed, preliminary evidence suggests that VEGFR-TKIs can reverse immunosuppressive effects in the tumor microenvironment, potentially enhancing the effects of subsequent immunotherapy with checkpoint inhibitors. However, questions remain regarding the most effective treatment sequences or combinations with VEGFR-TKIs and checkpoint inhibitors. This review discusses the potential role of first-line VEGFR-TKIs in priming the tumor microenvironment for immunotherapy.",
keywords = "Carcinoma, immunotherapy, pazopanib, renal cell, renal cell carcinoma, tyrosine kinase inhibitor, vascular endothelial growth factor",
author = "Nizar Tannir and Hans Hammers and Asim Amin",
year = "2018",
month = "5",
day = "4",
doi = "10.1080/03007995.2018.1423960",
language = "English (US)",
volume = "34",
pages = "825--831",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Taylor and Francis Ltd.",
number = "5",

}

TY - JOUR

T1 - First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma

T2 - priming the tumor microenvironment for immunotherapy

AU - Tannir, Nizar

AU - Hammers, Hans

AU - Amin, Asim

PY - 2018/5/4

Y1 - 2018/5/4

N2 - Despite improved outcomes with systemic vascular endothelial growth factor (VEGF)-targeted agents in patients with advanced renal cell carcinoma (RCC), the majority of patients will eventually develop treatment resistance and disease progression. With the emergence of checkpoint inhibitors as potential treatment approaches, studies suggest that ideally combining or sequencing them with VEGF receptor (VEGFR)–tyrosine kinase inhibitors (TKIs) may provide more effective treatments that reduce or delay disease progression. Indeed, preliminary evidence suggests that VEGFR-TKIs can reverse immunosuppressive effects in the tumor microenvironment, potentially enhancing the effects of subsequent immunotherapy with checkpoint inhibitors. However, questions remain regarding the most effective treatment sequences or combinations with VEGFR-TKIs and checkpoint inhibitors. This review discusses the potential role of first-line VEGFR-TKIs in priming the tumor microenvironment for immunotherapy.

AB - Despite improved outcomes with systemic vascular endothelial growth factor (VEGF)-targeted agents in patients with advanced renal cell carcinoma (RCC), the majority of patients will eventually develop treatment resistance and disease progression. With the emergence of checkpoint inhibitors as potential treatment approaches, studies suggest that ideally combining or sequencing them with VEGF receptor (VEGFR)–tyrosine kinase inhibitors (TKIs) may provide more effective treatments that reduce or delay disease progression. Indeed, preliminary evidence suggests that VEGFR-TKIs can reverse immunosuppressive effects in the tumor microenvironment, potentially enhancing the effects of subsequent immunotherapy with checkpoint inhibitors. However, questions remain regarding the most effective treatment sequences or combinations with VEGFR-TKIs and checkpoint inhibitors. This review discusses the potential role of first-line VEGFR-TKIs in priming the tumor microenvironment for immunotherapy.

KW - Carcinoma

KW - immunotherapy

KW - pazopanib

KW - renal cell

KW - renal cell carcinoma

KW - tyrosine kinase inhibitor

KW - vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=85045691716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045691716&partnerID=8YFLogxK

U2 - 10.1080/03007995.2018.1423960

DO - 10.1080/03007995.2018.1423960

M3 - Review article

C2 - 29297707

AN - SCOPUS:85045691716

VL - 34

SP - 825

EP - 831

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 5

ER -